Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objectives: This study aims to analyze the association of the presence of common polymorphisms [single nucleotide polymorphisms (SNPs)] on Toll-like receptors (TLRs), such as TLR9-1635A/G, TLR2-1892A/C, TLR2-2258G/A, TLR4-899A/G, and TLR4-1196C/T, with the viral rebound after stopping antiretroviral treatment (ART). CCR5-Δ32 deletion and HLA-A/HLA-B alleles were also analyzed.

Design: Interruption of ART may be required to investigate the outcome of strategies aimed to achieve drug-free HIV remission or cure. However, interruption of ART is currently not indicated. This was a retrospective longitudinal study that included 57 long-term suppressed HIV-1-infected individuals.

Methods: TLR SNPs were detected by real-time polymerase chain reaction (PCR). CCR5-Δ32 was analyzed by conventional PCR and HLA-A and HLA-B alleles by PCR-SSOP Luminex.

Results: HIV-1 RNA rebound at week 4 after treatment interruption positively correlated with pre-ART HIV-1 load (P = 0.025). The TLR9-1635AA genotype was independently associated with a higher HIV-1 rebound compared with those with AG + GG genotype (multivariate stepwise regression analysis, P = 0.004). Women had lower HIV-1 RNA load both at rebound and during the 72 weeks of follow-up compared with men (P < 0.05 at all time-points), whereas CD4 nadir and CD4 count set-point were similar according to sex. The pre-ART viral load was independently associated with the viral set-point (P = 0.001), whereas the presence of the HLA-A01 allele (P = 0.027) and the CD4 nadir (P = 0.001) were associated with the CD4 count set-point.

Conclusions: The association of the TLR9-1635AA genotype with a higher HIV-1 rebound suggests that this SNP may affect the results from strategies requiring interruption of ART aimed to cure HIV-1 infection.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019827PMC
http://dx.doi.org/10.1097/QAI.0000000000002437DOI Listing

Publication Analysis

Top Keywords

hiv-1 rebound
12
interruption art
12
rebound weeks
8
hiv-1 rna
8
tlr9-1635aa genotype
8
independently associated
8
higher hiv-1
8
cd4 nadir
8
cd4 count
8
hiv-1
7

Similar Publications

The vast majority of persons living with HIV-1 who discontinue antiretroviral therapy (ART) demonstrate viral rebound, but the tissue-level events that lead to rebound viremia are poorly understood. Here we report the origin, dynamics, and correlates of viral rebound in 16 rhesus macaques (RMs) infected with molecularly barcoded SIVmac239M, treated with ART for 70 weeks, and necropsied on day 12 after ART discontinuation. Barcode analysis of plasma following ART discontinuation identified 1 to 38 rebounding barcode-defined viral lineages per animal, with 1 to 4 rebounding lineages contributing to first measurable rebound viremia.

View Article and Find Full Text PDF

[Recent advances in research of cure of HIV infection].

Rinsho Ketsueki

September 2025

Department of Hematology, Graduate School of Medicine, Kyoto University.

Antiretroviral therapy (ART) is a well-established treatment for HIV infection that suppresses viral replication by inhibiting viral enzymatic activity, thereby preventing progression to immunodeficiency. However, discontinuation of ART typically leads to rapid viral rebound within weeks, due to the reactivation of latent HIV from long-lived reservoirs such as resting CD4 T cells. Eradication of these latent reservoirs is essential to achieve a cure for HIV.

View Article and Find Full Text PDF

Antiretroviral therapy (ART) suppresses viral replication in most people living with HIV-1 (PLWH). However, PLWH remain at risk of viral rebound. HIV-1 infection modifies the content of extracellular vesicles (EVs).

View Article and Find Full Text PDF

BACH2 promotes seeding and establishment of long-lived HIV-1 reservoir in memory CD4 T cells.

Cell Rep Med

August 2025

Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA; Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, MO, USA. Electronic address: shanliang@

Despite antiretroviral therapy, HIV-1 mainly persists in memory CD4 T cells in people living with HIV-1. Most long-lived viral reservoir cells are infected by the virus near the time of therapy initiation. A better understanding of the early events in viral reservoir seeding presents opportunities for preventing latent reservoir formation.

View Article and Find Full Text PDF

Virological and Immunological Outcomes of Combined Therapeutic Interventions and Dendritic Cell Therapy in People Living with HIV.

J Infect Dis

August 2025

Laboratório de Retrovirologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, Sao Paulo, Brazil.

Background: Several strategies have been devised to decrease the size of the HIV reservoir. Except for hematopoietic cell transplantation, therapeutic-driven HIV-1 curative approaches have had limited success. Here we describe a two-step randomized clinical trial designed to evaluate the safety and impact of individual and combinatorial therapeutic strategies on changes in peripheral and gut mucosal HIV reservoirs, immune activation and immune function in people living with HIV in the chronic disease stage of disease and presenting with high CD4 T cell nadirs.

View Article and Find Full Text PDF